Etalanetug
Based on 1 Customer Validation
Etalanetug (E2814) is a humanized high-affinity IgG1 antibody that targets tau protein and can cross the blood-brain barrier. Etalanetug inhibits the spread of pathological tau protein through high-affinity binding to the microtubule-binding region (MTBR). Etalanetug can be used in research related to Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity : 99.857%
- CAS No.: 2690265-18-8
- Molecular Weight:146.3 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
MAPT
In Vitro
Etalanetug (2 μg/mL) binds to recombinant human wild-type 2N4R tau protein with a high affinity of 88 pKd[2].
Etalanetug binds to recombinant human 2N3R tau protein in a dose-dependent manner, with slightly reduced affinity relative to 2N4R tau[2].
Etalanetug (8.3 μM; 30 min pre-incubation, 6 days aggregation) potently inhibits heparin-induced aggregation of both recombinant wild-type and P301S mutant 2N4R tau protein in vitro[2].
Etalanetug (0.3-10 μg; 48 h at 37 °C under 5% CO2) immunodepletes tau seeds (K18 fibrils and full-length P301S tau monomer) in a dose-dependent manner, reducing intracellular tau deposition in Lenti-X 293 T cells overexpressing P301S 0N4R tau[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Fetal-tau/0N3R Protein, Human (His, solution, HY-P73618) can bind Etalanetug. The EC50 for this effect is 1.246 ng/mL. -
Flow cytometric analysis of 1X106 SH-SY5Y cells labeling Tau with Etalanetug (HY-P990995, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2690265-18-8
-
Appearance Liquid
-
Molecular Weight 146.3 kDa
-
Color Colorless to light yellow
-
SMILES
[Etalanetug]
-
Synonyms
E2814
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Rawal S,et al. An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects. Alzheimer Dis Assoc Disord. 2025 Jul-Sep 01;39(3):151-157. [Content Brief]
[2]. Roberts M, et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020;8(1):13. Published 2020 Feb 4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)